Tango Therapeutics (TNGX) concentration risks

The company's disclosed concentration profile is defined by two high-share exposures — one pipeline and one supply chain — both of which are dependency-character risks that leave the company with little operational redundancy at this stage of development. The lead pipeline program, vopimetostat, is the primary focus of current clinical development — a high-share, mixed-character exposure. The mixed character acknowledges that concentrating resources on a lead asset is a deliberate scientific strategy, but the degree of concentration means that clinical setbacks, safety signals, or regulatory delays in the vopimetostat program would directly challenge the company's near-term development path with no comparably mature backup program. The manufacturing side compounds this picture. All manufacturing of drug substance for the company's product candidates used in clinical trials is conducted by one manufacturer — a high-share, dependency-character exposure with no disclosed alternative. For a clinical-stage company, a sole-source drug substance manufacturer represents a single point of failure: a quality hold, a capacity constraint, or the loss of the manufacturer relationship would delay or halt clinical supply, which in turn would disrupt trial timelines and extend the path to potential regulatory approval. The two exposures interact in a straightforward and concerning way: the company's most important clinical program depends on a single manufacturer for its drug supply. A failure at either node — program or supplier — cascades to the other. There is no disclosed diversification across either the clinical pipeline or the manufacturing network to provide a buffer, which is the defining feature of the company's current concentration profile.

For the engine’s reasoning on TNGX’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.

Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.